![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 9 of 9. This is the beginning of the thread.
Posted by SLS on October 29, 2010, at 17:17:51
Lurasidone HCI (Latuda) tablets have been approved by the U.S. Food and Drug Administration to treat adult schizophrenia
- Scott
Posted by SLS on October 29, 2010, at 17:25:15
In reply to New antipsychotic, posted by SLS on October 29, 2010, at 17:17:51
Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned human receptors or membrane fractions prepared from animal tissue. Lurasidone was found to have potent binding affinity for dopamine D2, 5-hydroxytryptamine 2A (5-HT2A), 5-HT7, 5-HT1A, and noradrenaline α2C receptors. Affinity for noradrenaline α1, α2A, and 5-HT2C receptors was weak, whereas affinity for histamine H1 and muscarinic acetylcholine receptors was negligible. In vitro functional assays demonstrated that lurasidone acts as an antagonist at D2 and 5-HT7 receptors and as a partial agonist at the 5-HT1A receptor subtype. Lurasidone showed potent effects predictive of antipsychotic activity, such as inhibition of methamphetamine-induced hyperactivity and apomorphine-induced stereotyped behavior in rats, similar to other antipsychotics. Furthermore, lurasidone had only weak extrapyramidal effects in rodent models. In animal models of anxiety disorders and depression, treatment with lurasidone was associated with significant improvement. Lurasidone showed a preferential effect on the frontal cortex (versus striatum) in increasing dopamine turnover. Anti-α1-noradrenergic, anticholinergic, and central nervous system (CNS) depressant actions of lurasidone were also very weak. These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects.
Posted by maxime on October 29, 2010, at 18:08:22
In reply to New antipsychotic, posted by SLS on October 29, 2010, at 17:17:51
> Lurasidone HCI (Latuda) tablets have been approved by the U.S. Food and Drug Administration to treat adult schizophrenia
>
>
> - ScottHow soon until it hits the market? Was it being used elsewhere before it was approved by the U.S.?
Posted by morgan miller on October 29, 2010, at 19:22:39
In reply to Re: New antipsychotic » SLS, posted by maxime on October 29, 2010, at 18:08:22
> > Lurasidone HCI (Latuda) tablets have been approved by the U.S. Food and Drug Administration to treat adult schizophrenia
> >
> >
> > - Scott
>
> How soon until it hits the market? Was it being used elsewhere before it was approved by the U.S.?Available in pharmacies in February 2011. That's what the website says. I might be trying this one. Though I'm never crazy about antagonizing dopamine receptors-one of the reasons why I'm not taking an AP right now.
Posted by linkadge on October 29, 2010, at 19:38:13
In reply to Re: New antipsychotic, posted by morgan miller on October 29, 2010, at 19:22:39
Seems like a promising agent.
Linkadge
Posted by bleauberry on October 29, 2010, at 21:24:52
In reply to New antipsychotic, posted by SLS on October 29, 2010, at 17:17:51
On paper this one looks promising. Thanks for sharing.
Posted by SLS on October 30, 2010, at 5:33:15
In reply to Re: New antipsychotic, posted by bleauberry on October 29, 2010, at 21:24:52
> On paper this one looks promising. Thanks for sharing.
It's too bad we can't eat paper.
:-)
- Scott
Posted by lamictal on November 1, 2010, at 12:47:36
In reply to New antipsychotic, posted by SLS on October 29, 2010, at 17:17:51
> Lurasidone HCI (Latuda) tablets have been approved by the U.S. Food and Drug Administration to treat adult schizophrenia
>
>
> - ScottI've just started low dose geodon in addition to lamictal and it has added to the ad effect of lamictal. I'm quite pleased with that.
what ad advantages does this new drug add have that geodon does not? Also bipolar effects that geodon does not?
I am asking you as you seem extremely knowedgable in the area of pyschotropic meds.
Thank you!
Posted by SLS on November 1, 2010, at 13:50:49
In reply to Re: New antipsychotic, posted by lamictal on November 1, 2010, at 12:47:36
> > Lurasidone HCI (Latuda) tablets have been approved by the U.S. Food and Drug Administration to treat adult schizophrenia
> >
> >
> > - Scott
>
> I've just started low dose geodon in addition to lamictal and it has added to the ad effect of lamictal. I'm quite pleased with that.
>
> what ad advantages does this new drug add have that geodon does not? Also bipolar effects that geodon does not?
>
> I am asking you as you seem extremely knowedgable in the area of pyschotropic meds.
>
> Thank you!It will probably be a little while before the clinical properties of lurasidone are elucidated through usage. Geodon might act more as an antidepressant because it is a reuptake inhibitor of both serotonin and norepinephrine. To my knowledge, lurasidone does not do these things.
- Scott
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.